Varenicline for smoking cessation: A placebo‐controlled, randomized study

Abstract

Varenicline was significantly more efficacious for smoking cessation than placebo over a 12-week treatment period and a further 12-week non-treatment follow-up period in smokers from China, Singapore and Thailand. No significant side-effects were noted.

Safety and Tolerability of Varenicline Tartrate (Champix®/Chantix®) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study

“…We found seven published RCTs conducted in generally healthy smokers, with at least one arm using varenicline 1.0 mg twice a day for 12 weeks, serving as our external comparison studies. [28][29][30][31][32][33][34] Incidence rates in overall AE and nausea in our study were comparable to those in external comparison studies (Table 3), however, we had a significantly higher incidence rate of abnormal dreams (31% versus 9%, p < 0.001) and a higher discontinuation rate (28% versus 13%, p = 0.011).…”

“…We also detected small but statistically significant changes in diastolic blood pressure, which were not associated with weight change. On the other hand, in three external comparison studies we used, only one case of ALT elevation was reported respectively, 28,30,31 and no significant change in blood pressure was reported in any external comparison study. Although inconclusive, due to limitations in our study, our results suggest that HIV-positive patients taking varenicline may benefit from monitoring of their liver enzymes and blood pressure.…”

Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

“…After the removal of duplicates and screening of titles and abstracts, 68 trials underwent full‐text review. In total, 38 RCTs met all eligibility criteria and were included in our meta‐analysis 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49…”

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

“…Only two studies matching the inclusion criteria that evaluated cytisine were identified, 17,43 compared with 21 studies of varenicline. 16,[37][38][39]41,[46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] The varenicline data include studies of its clinical effectiveness in a number of real-world settings, which allows their results to be generalised to wider populations. Cytisine has yet to be studied in subpopulations.…”